ReviewCancers2022
Hepatocellular Carcinoma Recurrence and Mortality Rate Post Liver Transplantation: Meta-Analysis and Systematic Review of Real-World Evidence.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Post-Transplant HCC Recurrence and Survival: Impact of Bridging Therapy and Tumor Biology in 185 Consecutive Liver Transplants.Journal of clinical medicine · 2026Article
- Comparison of Sevoflurane and Desflurane on Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation: A Propensity Score-Matched Analysis.Medicina (Kaunas, Lithuania) · 2026Article
- Recurrence of Colorectal Cancer After Liver Transplant for Isolated Colorectal Liver Metastases: A Narrative Review.Cancers · 2026Review
- HCC recurrence in liver transplants treated with hypothermic oxygenated machine perfusion: An international matched cohort study.JHEP reports : innovation in hepatology · 2026Article
- Prognosis of liver transplantation and hepatectomy in patients with hepatocellular carcinoma meeting the Milan criteria: A systematic review and meta-analysis.Oncology letters · 2026Article
- Emerging role of low-frequency somatic mutations in cancer relapse: from early detection to precision oncology.Frontiers in oncology · 2026Review
- Screening for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Prospective Validation of Binary Criteria.Cancer medicine · 2025Article
- Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions.Journal of clinical medicine · 2025Review
- Explant-based prognostic models for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis.World journal of hepatology · 2025Article
- Hepatocellular carcinoma recurrence after liver transplant: An Australian single-centre study.World journal of transplantation · 2025Article
- The far side of the moon: trans-thoracic minimally invasive resection of local recurrence of hepatocarcinoma following liver transplantation using intraoperative transdiaphragmatic ultrasound: a case report.Journal of visualized surgery · 2025Article
- Recipient-Donor Sex Constellation in Liver Transplantation for Hepatocellular Carcinoma-An ELTR Study.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Long-Term Prognostic Value of AFP and PIVKA-II in HCC After Living Donor Liver Transplantation: A Single-Center Retrospective Study.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Mechanisms of Tolerance Induction in Liver Transplantation: Lessons Learned from Fetomaternal Tolerance, Autoimmunity and Tumor Immunity.International journal of molecular sciences · 2024Review
- Article
- Deciphering the role of KLRB1: a novel prognostic indicator in hepatocellular carcinoma.BMC gastroenterology · 2024Article
- Fluorescence/electrochemical dual-mode strategy for Golgi protein 73 detection based on molybdenum disulfide/ferrocene/palladium nanoparticles and nitrogen-doped graphene quantum dots.Mikrochimica acta · 2024Article
- Liver Stiffness Values to Predict Occurrence and Recurrence of Hepatocellular Carcinoma.Life (Basel, Switzerland) · 2024Review
- Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues.Cancers · 2023Review
- Comprehensive clinicopathological significance and putative transcriptional mechanisms of Forkhead box M1 factor in hepatocellular carcinoma.World journal of surgical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundliver transplantation (LT) is the best curative option for eligible patients with hepatocellular carcinoma (HCC), however recurrence remains a major concern. This meta-analysis aimed to investigate the prevalence and risk factors of HCC recurrence.
methodsstudies were selected using PubMed, Epistemonikas, and Google Scholar databases published from inception to 15 May 2022 and a meta-analysis of the proportions was conducted. Observational studies reporting the prevalence of recurrent HCC after an LT were included, with the analysis being stratified by an adherence to the Milan criteria (MC), geographical region, AFP levels, and donor type.
resultsout of 4081 articles, 125 were included in the study. The prevalence of recurrent HCC was 17% (CI: 15-19). Patients beyond the MC were more likely to recur than patients within the MC. Asian populations had the greatest prevalence of HCC recurrence (21%; CI: 18-24), whereas North American populations had the lowest recurrence (10%; CI: 7-12). The mortality rate after HCC recurrence was 9%; CI: 8-11. North American populations had the greatest prevalence of mortality with 11% (CI: 5-17).
conclusionsthe recurrence, overall survival, and mortality rates among patients with HCC post-LT remains high, with substantial differences between regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.